Ã
Expand
The breath biomarker panel, which is now commercially available, is intended to support research to distinguish between different types of chronic inflammatory airway diseases including asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF), and to facilitate better therapeutic decision making and monitoring.
Owlstone Medicalâs Respiratory Diseases RUO Panel consists of a set of biologically relevant Volatile Organic Compounds (VOCs) that have been linked to inflammatory respiratory diseases and can be easily collected on breath to enable direct characterisation of disease biology in the lungs by non-invasively sampling the airways.Â
Available as an early output from the companyâs test development process and supported by scientific publications and Breath Biopsy client study data, the Panel will initially be offered for Research Use Only as part of an expanded Breath Biopsy Products and Services offering to supplement the Breath Biopsy OMNI Assay. It will be used by pharmaceutical and academic/clinical research clients to support therapeutic development through characterisation of disease endotypes and monitoring response to therapy, and to better understand the onset, development and exacerbation of disease. Building from this Panel, an in vitro diagnostic (IVD) is intended to be developed to support treatment decision making through patient stratification and monitoring of therapeutic response.  Â